Epigral consolidated net profit rises 27.06% in the September 2026 quarter

Sales rise 27.01% to Rs 745.99 crore

Net profit of Epigral rose 27.06% to Rs 65.08 crore in the quarter ended September 2026 as against Rs 51.22 crore during the previous quarter ended September 2025. Sales rose 27.01% to Rs 745.99 crore in the quarter ended September 2026 as against Rs 587.36 crore during the previous quarter ended September 2025.

Particulars	Quarter Ended
	Sep. 2026	Sep. 2025	% Var.
Sales	745.99	587.36	27
OPM %	18.25	22.48	-
PBDT	131.81	111.96	18
PBT	87.58	69.65	26
NP	65.08	51.22	27

Powered by Capital Market - Live News